•   English  
  • /
  •   中文
山东方坦思生物医药产业技术研究院有限公司
HOMEHome
WHO WE ARENav
WHAT WE DONav
INVESTORSNav
PIPELINENav
NEWSNav
CAREERSNav
CONTACT USNav
HISTORYLEADERSHIPADVISORSBOARD OF DIRECTORS
Fontacea was invited to participate in the "ICBC Cup · Shanghai Lingang Innovative Design and Entrep
[ news ] 2021-05-19
Fontacea and Thousand Oaks reach strategic cooperation
[ news ] 2021-04-13
Fontacea takes action in promoting the R&D and innovation of Chinese biomedicine
[ news ] 2020-12-21
Fontacea supports Guzhang through alleviating poverty
[ news ] 2020-06-24
"Innovate together to win the future" Fontacea successfully held the launch ceremony in Shenzhen
[ news ] 2020-04-12
Mr Yanliang Chu, chairman of Fontacea, signed Dr David Brooks as business consultant in USA
[ news ] 2020-02-10
Mr Yanliang Chu, Chairman of Fontacea, signed Dr Timothy P. Coogan as the Medicine Safety Consultant
[ news ] 2019-12-23
Senior leaders attended "Innovative Medicine Investment Seminar"
[ news ] 2019-12-11
Shandong Fontacea is licensed for anti-IL17A monoclonal antibody from Janssen
[ news ] 2019-09-10
Yanliang Chu, welcomes Mark Winnett as Management Consultant to Fontacea
[ news ] 2019-08-12
Fontacea shareholder Lei Meng, chairman of Shandong development investment holding group co. LTD
[ news ] 2019-07-17

to the end ~

©2020 -  Shandong Fontacea Pharmaceutical Institute Co.,Ltd copyright.
| 本站支持  --